Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | DRD3 | P35462 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15473290 | 0.86 | HCAR2 (0.38) | HCAR2MEN1KMT2AHSP90AA1HSP90AB1 | |
| SCHEMBL9911981 | 0.84 | HCAR2 (0.39) | HCAR2MEN1KMT2AHSP90AA1HSP90AB1 | |
| SCHEMBL12650126 | 0.83 | HCAR2 (0.35) | HCAR2MEN1KMT2AHSP90AA1HSP90AB1 | |
| SCHEMBL171117 | 0.81 | KMT2A (0.48) | HCAR2MEN1KMT2ACHRNB2CHRNA4 | |
| SCHEMBL16996976 | 0.80 | HCAR2 (0.36) | HCAR2MEN1KMT2AHSP90AA1HSP90AB1 | |
| SCHEMBL9868320 | 0.77 | HCAR2 (0.42) | HCAR2MEN1KMT2ACNR2POLB | |
| SCHEMBL20320520 | 0.77 | HCAR2 (0.38) | HCAR2MEN1KMT2ACNR2CHRNB2 | |
| SCHEMBL2585198 | 0.77 | HCAR2 (0.38) | HCAR2MEN1KMT2ACNR2CHRNB2 | |
| SCHEMBL2585201 | 0.77 | HCAR2 (0.38) | HCAR2MEN1KMT2ACNR2CHRNB2 | |
| SCHEMBL10072176 | 0.77 | MLYCD (0.39) | HCAR2POLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10744155-B2 | Inhibitors of ADAMTS4 or ADAMTS5 for use in preventing or treating cardiac remodeling and chronic heart failure | UNIVERSITETET I OSLO (NO) | 2020-08-18 | — | — | US | disclosed |
| US-20190282606-A1 | INHIBITORS OF ADAMTS4 OR ADAMTS5 FOR USE IN PREVENTING OR TREATING CARDIAC REMODELING AND CHRONIC HEART FAILURE | UNIVERSITETET I OSLO (NO) | 2019-09-19 | — | — | US | disclosed |
| US-10322143-B2 | Inhibitors of ADAMTS4 or ADAMTS5 for use in preventing or treating cardiac remodeling and chronic heart failure | UNIVERSITETET I OSLO (NO) | 2019-06-18 | — | — | US | disclosed |
| US-20160158271-A1 | INHIBITORS OF ADAMTS4 OR ADAMTS5 FOR USE IN PREVENTING OR TREATING CARDIAC REMODELING AND CHRONIC HEART FAILURE | UNIVERSITETET I OSLO (NO) | 2016-06-09 | — | — | US | disclosed |
| US-20160158271-A1 | INHIBITORS OF ADAMTS4 OR ADAMTS5 FOR USE IN PREVENTING OR TREATING CARDIAC REMODELING AND CHRONIC HEART FAILURE | UNIVERSITETET I OSLO (NO) | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10322143-B2 | Inhibitors of ADAMTS4 or ADAMTS5 for use in preventing or treating cardiac remodeling and chronic heart failure | ADAMTS5, ADAMTS4, ADAMTS1 | HCAR2 1229/4885MEN1 3006/4885KMT2A 2260/4885 |
| US-20190282606-A1 | INHIBITORS OF ADAMTS4 OR ADAMTS5 FOR USE IN PREVENTING OR TREATING CARDIAC REMODELING AND CHRONIC HEART FAILURE | ADAMTS5, ADAMTS4, ADAMTS1 | HCAR2 1229/4885MEN1 3006/4885KMT2A 2260/4885 |
| US-20160158271-A1 | INHIBITORS OF ADAMTS4 OR ADAMTS5 FOR USE IN PREVENTING OR TREATING CARDIAC REMODELING AND CHRONIC HEART FAILURE | ADAMTS5, ADAMTS4, ADAMTS1 | HCAR2 1229/4885MEN1 3006/4885KMT2A 2260/4885 |
| US-10744155-B2 | Inhibitors of ADAMTS4 or ADAMTS5 for use in preventing or treating cardiac remodeling and chronic heart failure | ADAMTS5, ADAMTS4, ADAMTS1 | HCAR2 1229/4885MEN1 3006/4885KMT2A 2260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.